デング熱ワクチンの世界市場レポート 2025年

デング熱ワクチンの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.3％で11億4,000万米ドルに成長します。予測期間の成長は、デング熱の発生率の増加、複数の組織によるイニシアチブの増加、臨床試験の増加、多系統および4価ワクチン製剤の重視の高まりに起因すると考えられます。予測期間における主な動向としては、予防ワクチン需要の増加、ワクチン技術の進歩、混合ワクチンの開発、新規ワクチン候補の研究・臨床試験の増加、ワクチンの有効性と安全性プロファイルの改善への注力などが挙げられます。

デング熱患者数の増加が、今後数年間のデング熱ワクチン市場の成長を牽引すると予想されます。デング熱はヒトスジシマカによって媒介されるウイルス感染症で、高熱、頭痛、関節痛、発疹などの症状を引き起こします。デング熱患者の増加は、気候変動、都市化、不十分な蚊の駆除、ウイルスの進化などの要因によるものと考えられています。デング熱ワクチンは、デングウイルスを認識して闘う免疫系を活性化し、感染症の重症度を下げ、重篤な合併症のリスクを低下させることで、患者数や入院数を減少させる機能を果たします。例えば、スイスに本部を置く世界保健機関（WHO）は2024年5月、南北南北アメリカにおけるデング熱感染者が2023年の460万人から2024年4月には700万人を超えたと報告しました。このように、デング熱の罹患率の増加がデング熱ワクチン市場の成長を促進しています。

デング熱ワクチン市場の主要企業は、単一のワクチンで4つのデングウイルス血清型すべてに対する防御を強化するデング4価ワクチンなど、高度なワクチン製剤の開発に注力しています。デング4価ワクチンは、4つのデング血清型（DEN-1、DEN-2、DEN-3、DEN-4）に対する免疫を提供し、デング熱に対する包括的な防御を提供します。例えば、2022年12月、日本の製薬会社である武田薬品工業は、欧州委員会から4歳以上の個人を対象としたQDENGAワクチンの使用承認を取得しました。この弱毒化ワクチンは、デング熱の流行国でデング熱の予防に使用されているもので、デング熱の血清型2のウイルスを弱毒化し、他の3つの血清型の遺伝的基盤としています。0.5mLずつ2回に分けて0ヵ月と3ヵ月に投与され、対象年齢は4歳以上です。第3相臨床試験の結果、QDENGAのデング熱に対する有効性は約80.2％で、特に入院の予防において良好な結果が示されました。その予防効果は約4.5年持続すると予想されており、これは他の多くのワクチンよりも長いです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界デング熱ワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のデング熱ワクチン市場：成長率分析
• 世界のデング熱ワクチン市場の実績：規模と成長, 2019-2024
• 世界のデング熱ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界デング熱ワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のデング熱ワクチン市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生弱毒化ワクチン
• キメラ生弱毒化ワクチン
• 不活化ワクチン
• サブユニットワクチン
• 核酸ベースのワクチン
• 世界のデング熱ワクチン市場ワクチン段階別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェーズI
• フェーズII
• フェーズIII
• 世界のデング熱ワクチン市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 利尿
• 抗アレルギー
• 血液凝固阻止剤
• その他の治療法
• 世界のデング熱ワクチン市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界のデング熱ワクチン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 政府機関
• 非政府組織
• その他のエンドユーザー
• 世界のデング熱ワクチン市場生弱毒化ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単一株
• マルチストレイン
• 世界のデング熱ワクチン市場キメラ生弱毒化ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 四価キメラワクチン
• 一価キメラワクチン
• 世界のデング熱ワクチン市場不活化ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全ウイルス不活化ワクチン
• スプリットウイルスワクチン
• 世界のデング熱ワクチン市場、サブユニットワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換えタンパク質ワクチン
• ペプチドベースのワクチン
• 世界のデング熱ワクチン市場核酸ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• DNAワクチン
• mRNAワクチン

第7章 地域別・国別分析

• 世界のデング熱ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のデング熱ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• デング熱ワクチン市場：競合情勢
• デング熱ワクチン市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Pasteur Limited Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Overview, Products and Services, Strategy and Financial Analysis
  • Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Biological E. Limited
• Saint Louis University
• Indian Immunologicals Limited
• Serum Institute of India Pvt. Ltd.
• Bavarian Nordic
• Instituto Butantan
• Bharat Biotech Ltd.
• Panacea Biotec Limited
• SABIN Vaccine Institute
• Medigen Vaccine Biologics Corporation
• Emergex Vaccines Holding Ltd.
• BioNet-Asia Co. Ltd.
• Codagenix Inc.
• KM Biologics Co. Ltd.
• Chula Vaccine Research Center

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• デング熱ワクチン市場2029：新たな機会を提供する国
• デング熱ワクチン市場2029：新たな機会を提供するセグメント
• デング熱ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A dengue vaccine is a biological preparation aimed at preventing dengue fever, a viral disease transmitted by mosquitoes and caused by the dengue virus (DENV). When exposed to the virus in the future, dengue vaccines help stimulate the body's immune system to recognize and combat the dengue virus.

The primary types of dengue vaccines include live attenuated vaccines, chimeric live attenuated vaccines, inactivated vaccines, subunit vaccines, and nucleic acid-based vaccines. Live attenuated vaccines utilize a weakened form of the virus to elicit an immune response, training the body to fight dengue without causing the illness. These vaccines undergo various phases of development, including phase I, phase II, and phase III trials, and treatments associated with dengue may involve diuretics, anti-allergics, blood thinners, among others. They can be administered through different routes, such as oral and parenteral, and are used by a variety of end users, including hospitals, clinics, government institutions, and non-governmental organizations.

The dengue vaccines market research report is one of a series of new reports from The Business Research Company that provides dengue vaccines market statistics, including dengue vaccines industry global market size, regional shares, competitors with a dengue vaccines market share, detailed dengue vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the dengue vaccines industry. This dengue vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dengue vaccine market size has grown rapidly in recent years. It will grow from $0.64 billion in 2024 to $0.72 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to growing travel and urbanization, increasing demand for effective vaccines, increasing prevalence of foreign travel exposure, increasing healthcare services, and rising mass vaccinations.

The dengue vaccine market size is expected to see rapid growth in the next few years. It will grow to $1.14 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to the increasing incidence of dengue, increasing initiatives by several organizations, increasing clinical trials, and growing emphasis on multi-strain and tetravalent vaccine formulations. Major trends in the forecast period include increasing demand for preventative vaccines, advancements in vaccine technology, development of combination vaccines, rise in research and clinical trials for new vaccine candidates, and focus on improving vaccine efficacy and safety profiles.

The increasing number of dengue fever cases is anticipated to drive the growth of the dengue vaccine market in the coming years. Dengue fever is a viral infection transmitted by Aedes aegypti mosquitoes, leading to symptoms such as high fever, headaches, joint pain, and rashes. The rise in dengue cases can be attributed to factors such as climate change, urbanization, insufficient mosquito control, and the evolution of the virus. The dengue vaccine functions by activating the immune system to recognize and fight the dengue virus, reducing the severity of infections and lowering the risk of severe complications, which helps decrease the number of cases and hospitalizations. For example, in May 2024, the World Health Organization, based in Switzerland, reported that dengue cases in the Americas exceeded 7 million in April 2024, up from 4.6 million cases in 2023. Thus, the increasing incidence of dengue fever is propelling the growth of the dengue vaccine market.

Leading companies in the dengue vaccine market are focusing on developing advanced vaccine formulations, such as the dengue tetravalent vaccine, which enhances protection against all four dengue virus serotypes in a single vaccine. The dengue tetravalent vaccine provides immunity against the four dengue serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), offering comprehensive protection against dengue fever. For instance, in December 2022, Takeda Pharmaceutical Company, a pharmaceutical firm based in Japan, received approval from the European Commission for the use of the QDENGA vaccine in individuals aged four years and older. This live-attenuated vaccine is used in several dengue-endemic countries to protect against the disease and utilizes weakened dengue serotype two viruses as a genetic basis for the other three serotypes. It is administered in two doses of 0.5 mL each, given at 0 and 3 months, targeting individuals from the age of four and older. A Phase 3 trial indicated that QDENGA has an efficacy of approximately 80.2% against dengue, with particularly favorable results in preventing hospitalizations. Its protection is expected to last around 4.5 years, which is longer than many other vaccines.

In February 2024, Takeda Pharmaceutical Company entered into a partnership with Biological E. Limited, a biotechnology and biopharmaceutical company based in India. This collaboration aims to expedite the production and accessibility of the QDENGA (TAK-003) dengue vaccine in endemic regions by increasing manufacturing capacity and providing multi-dose vials to support national immunization initiatives.

Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Ltd., Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.

Asia-Pacific was the largest region in the dengue vaccine market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dengue vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dengue vaccine market consists of revenues earned by entities by providing treatment such as chlorothiazide, chlorthalidone, hydrochlorothiazide, and fexofenadine. The market value includes the value of related goods sold by the service provider or included within the service offering. The dengue vaccine market also includes sales of diagnostic kits, combination vaccines, clinical trial products, and post-vaccination monitoring tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dengue Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dengue vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dengue vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dengue vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Live Attenuated Vaccine; Chimeric Live Attenuated Vaccine; Inactivated Vaccine; Subunit Vaccine; Nucleic Acid Based Vaccine
• 2) By Vaccine Phase: Phase I; Phase II; Phase III
• 3) By Treatment: Diuretic; Anti-Allergic; Blood Thinners; Other Treatments
• 4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 5) By End-User: Hospitals; Clinics; Government Institutes; Non-Governmental Organizations; Other End-Users
• Subsegments:
• 1) By Live Attenuated Vaccine: Single Strain; Multi-Strain
• 2) By Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine; Monovalent Chimeric Vaccine
• 3) By Inactivated Vaccine: Whole Virus Inactivated Vaccine; Split Virus Vaccine
• 4) By Subunit Vaccine: Recombinant Protein Vaccine; Peptide-Based Vaccine
• 5) By Nucleic Acid Based Vaccine: DNA Vaccine; mRNA Vaccine
• Companies Mentioned: Merck & Co. Inc.; Sanofi Pasteur Limited; GlaxoSmithKline plc; Takeda Pharmaceutical Company; Sun Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dengue Vaccine Market Characteristics

3. Dengue Vaccine Market Trends And Strategies

4. Dengue Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Dengue Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Dengue Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Dengue Vaccine Market Growth Rate Analysis
• 5.4. Global Dengue Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Dengue Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Dengue Vaccine Total Addressable Market (TAM)

6. Dengue Vaccine Market Segmentation

• 6.1. Global Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Vaccine
• Chimeric Live Attenuated Vaccine
• Inactivated Vaccine
• Subunit Vaccine
• Nucleic Acid Based Vaccine
• 6.2. Global Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phase I
• Phase II
• Phase III
• 6.3. Global Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diuretic
• Anti-Allergic
• Blood Thinners
• Other Treatments
• 6.4. Global Dengue Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.5. Global Dengue Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Government Institutes
• Non-Governmental Organizations
• Other End-Users
• 6.6. Global Dengue Vaccine Market, Sub-Segmentation Of Live Attenuated Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Strain
• Multi-Strain
• 6.7. Global Dengue Vaccine Market, Sub-Segmentation Of Chimeric Live Attenuated Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tetravalent Chimeric Vaccine
• Monovalent Chimeric Vaccine
• 6.8. Global Dengue Vaccine Market, Sub-Segmentation Of Inactivated Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Whole Virus Inactivated Vaccine
• Split Virus Vaccine
• 6.9. Global Dengue Vaccine Market, Sub-Segmentation Of Subunit Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Protein Vaccine
• Peptide-Based Vaccine
• 6.10. Global Dengue Vaccine Market, Sub-Segmentation Of Nucleic Acid Based Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DNA Vaccine
• mRNA Vaccine

7. Dengue Vaccine Market Regional And Country Analysis

• 7.1. Global Dengue Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Dengue Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dengue Vaccine Market

• 8.1. Asia-Pacific Dengue Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dengue Vaccine Market

• 9.1. China Dengue Vaccine Market Overview
• 9.2. China Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dengue Vaccine Market

• 10.1. India Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dengue Vaccine Market

• 11.1. Japan Dengue Vaccine Market Overview
• 11.2. Japan Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dengue Vaccine Market

• 12.1. Australia Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dengue Vaccine Market

• 13.1. Indonesia Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dengue Vaccine Market

• 14.1. South Korea Dengue Vaccine Market Overview
• 14.2. South Korea Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dengue Vaccine Market

• 15.1. Western Europe Dengue Vaccine Market Overview
• 15.2. Western Europe Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dengue Vaccine Market

• 16.1. UK Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dengue Vaccine Market

• 17.1. Germany Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dengue Vaccine Market

• 18.1. France Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dengue Vaccine Market

• 19.1. Italy Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dengue Vaccine Market

• 20.1. Spain Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dengue Vaccine Market

• 21.1. Eastern Europe Dengue Vaccine Market Overview
• 21.2. Eastern Europe Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dengue Vaccine Market

• 22.1. Russia Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dengue Vaccine Market

• 23.1. North America Dengue Vaccine Market Overview
• 23.2. North America Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dengue Vaccine Market

• 24.1. USA Dengue Vaccine Market Overview
• 24.2. USA Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dengue Vaccine Market

• 25.1. Canada Dengue Vaccine Market Overview
• 25.2. Canada Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dengue Vaccine Market

• 26.1. South America Dengue Vaccine Market Overview
• 26.2. South America Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dengue Vaccine Market

• 27.1. Brazil Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dengue Vaccine Market

• 28.1. Middle East Dengue Vaccine Market Overview
• 28.2. Middle East Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dengue Vaccine Market

• 29.1. Africa Dengue Vaccine Market Overview
• 29.2. Africa Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dengue Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Dengue Vaccine Market Competitive Landscape
• 30.2. Dengue Vaccine Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi Pasteur Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Dengue Vaccine Market Other Major And Innovative Companies

• 31.1. Biological E. Limited
• 31.2. Saint Louis University
• 31.3. Indian Immunologicals Limited
• 31.4. Serum Institute of India Pvt. Ltd.
• 31.5. Bavarian Nordic
• 31.6. Instituto Butantan
• 31.7. Bharat Biotech Ltd.
• 31.8. Panacea Biotec Limited
• 31.9. SABIN Vaccine Institute
• 31.10. Medigen Vaccine Biologics Corporation
• 31.11. Emergex Vaccines Holding Ltd.
• 31.12. BioNet-Asia Co. Ltd.
• 31.13. Codagenix Inc.
• 31.14. KM Biologics Co. Ltd.
• 31.15. Chula Vaccine Research Center

32. Global Dengue Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dengue Vaccine Market

34. Recent Developments In The Dengue Vaccine Market

35. Dengue Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Dengue Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Dengue Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Dengue Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer